viewRevive Therapeutics

Revive Therapeutics reveals progress on oral thin film drug delivery technology for psilocybin and psychedelic-derived medicine

The company received the first set of orally dissolvable thin film strips that allow quick delivery to the bloodstream

Revive Therapeutics -
Revive said it plan to unveil the final prototype in the coming weeks

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) announced a new milestone in its psilocybin and psychedelic-derived drug delivery program.

The Toronto-based firm received the first set of orally dissolvable thin film strips that will deliver psilocybin and, further down the line, psychedelic-derived medicine to help treat various conditions.

Revive is working with Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.

READ: Revive Therapeutics to initiate Phase 3 coronavirus trial of Bucillamine in September

“We are very pleased about the progress we have achieved to date and this technical milestone for our drug delivery technology specifically in the development of an orally dissolvable thin film strip for psilocybin, which will be used in future human clinical studies,” said Michael Frank, CEO of Revive in a statement. 

“This is the first time that we have applied our drug delivery technology to oral thin films and we see great promise in delivering psychedelic-based medicines to treat various diseases and disorders that would benefit from such a delivery method and in partnering with life sciences companies seeking to add unique offerings in their product pipeline.”

The oral thin film strip dissolves rapidly, allowing quick delivery to the bloodstream without the need for water, chewing or swallowing, which could potentially improve therapeutic outcomes.

Revive said it plan to unveil the final prototype in the coming weeks.

Revive and Reed said it had identified tannin-chitosan composite of orally dissolvable thin films as the lead candidate to develop its delivery platform for therapeutic doses between one and 20 milligrams of psilocybin orally.

Also on Tuesday, the firm said it had granted 6 million stock options to an officer and director exercisable at C$0.33 for a five-year period.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: Revive Therapeutics

Price: 0.6 CAD

Market: CSE
Market Cap: $142.07 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company...


Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

on 30/6/20

2 min read